Recursion Pharmaceuticals, Inc.
RXRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $5 | $19 | $15 | $5 |
| % Growth | -72.9% | 29.6% | 226.9% | – |
| Cost of Goods Sold | $30 | $20 | $22 | $13 |
| Gross Profit | -$24 | -$1 | -$7 | -$8 |
| % Margin | -471.8% | -5.5% | -48% | -183.6% |
| R&D Expenses | $121 | $129 | $130 | $98 |
| G&A Expenses | $42 | $47 | $55 | $77 |
| SG&A Expenses | $42 | $47 | $55 | $77 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$15 | -$0 | $0 | -$0 |
| Operating Expenses | $148 | $175 | $184 | $175 |
| Operating Income | -$172 | -$176 | -$191 | -$184 |
| % Margin | -3,327.6% | -922.5% | -1,297.9% | -4,073.8% |
| Other Income/Exp. Net | $10 | $4 | -$11 | $5 |
| Pre-Tax Income | -$162 | -$172 | -$203 | -$179 |
| Tax Expense | $0 | $0 | -$0 | $0 |
| Net Income | -$162 | -$172 | -$202 | -$179 |
| % Margin | -3,135.3% | -899.8% | -1,373.3% | -3,966% |
| EPS | -0.36 | -0.41 | -0.5 | -0.53 |
| % Growth | 12.2% | 18% | 5.7% | – |
| EPS Diluted | -0.36 | -0.41 | -0.5 | -0.53 |
| Weighted Avg Shares Out | 447 | 417 | 403 | 336 |
| Weighted Avg Shares Out Dil | 447 | 417 | 403 | 336 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $5 | $5 | $5 |
| Interest Expense | $0 | $0 | $0 | $1 |
| Depreciation & Amortization | $21 | $24 | $19 | $13 |
| EBITDA | -$141 | -$148 | -$183 | -$165 |
| % Margin | -2,728.6% | -772.5% | -1,239.8% | -3,665.3% |